Hemispherx BioPharma, Inc (NYSE:HEB) announced its financial results for the nine months ended September 30, 2015. The net loss (including non-cash effects) was approximately $12,093,000 or $(0.05) per share as compared to a net loss of $12,994,000 or ($0.07) per share for the same nine month period in 2014.
Cash, cash equivalents and marketable securities were approximately $12,375,000 at September 30, 2015 as compared to $16,108,000 as of December 31, 2014.
On September 28, 2015, the Company announced formal granting of a new composition of matter patent by the European Patent Office on Ampligen® which may extend through year 2029 and potentially beyond. This important milestone was achieved through the efforts of William A. Carter, the company’s Chairman and CEO, leading a research team at the company’s wholly owned R and D laboratories in New Brunswick, NJ. The patents are expected to be issued in up to 25 countries.
Hemispherx Biopharma, Inc. will now collaborate with a new partner, myTomorrows, to provide access to its natural alpha interferon for patients that have become intolerant to treatment with recombinant interferon or where such treatment fails. Through myTomorrows’ Internet-based platform we plan to make this unique interferon formulation available to patients and doctors in Brazil, Columbia and Chile, through an Early Access Program.
We have recently expanded our international collaborative programs with both major components of our treatment platform (Ampligen®, an experimental therapeutic, and Alferon® N, an FDA approved commercial product, more fully described below) to create an expanded patient access path while seeking formal approval in the European Union, Australia, and New Zealand.
Our overall objectives also include plans to continue seeking approval for commercialization of Ampligen® in the United States and abroad as well as to widen existing commercial therapeutic indications of Alferon N Injection® presently approved for sales in the United States and Argentina. In addition, we have formed collaborations with multiple research laboratories around the world to examine Ampligen®, an experimental therapeutic, and Alferon N, an FDA-approved commercial product (for certain types of genital warts (HPV)), as potential preventatives for, and treatments of, Ebola Virus Disease (EVD) and other hazardous viruses including pandemic influenza and Middle East Respiratory Syndrome (MERS). Promising clinical results in immunotherapy of difficult-to-treat human malignancies with Ampligen® are also being aggressively pursued. Our ability to commercialize our products, widen commercial therapeutic indications of Alferon N Injection® and/or capitalize on our collaborations with research laboratories to examine our products as potential preventatives for, and treatments of newly emerging viral diseases are subject to a number of significant risks and uncertainties including, but not limited to, our ability to enter into more definitive agreements with some of the research laboratories and others with whom we are collaborating, to fund and conduct additional testing and studies, whether or not such testing is successful or requires additional testing and meets the requirements of the FDA and comparable foreign regulatory agencies. We do not know when, if ever, our products will be generally available for commercial sale for any new indications. (Original Source)
Shares of Hemispherx Biopharma closed yesterday at $0.15. HEB has a 1-year high of $0.33 and a 1-year low of $0.11. The stock’s 50-day moving average is $0.15 and its 200-day moving average is $0.19.
Hemispherx Biopharma Inc is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.